News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - IND
Glenmark Pharmaceuticals Enters Oncology With The Discovery And Initiation Of IND Enabling Studies Of An Innovative Bispecific Antibody 8/20/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces FDA Acceptance Of IND To Commence Clinical Trial Of VC-01™ Candidate Cell Replacement Therapy For Type 1 Diabetes 8/19/2014
FDA Grants Orphan Drug Designation For Oncosynergy's Investigational Monoclonal Antibody OS2966 In The Treatment Of Glioblastoma 8/12/2014
Phosphagenics Limited (POH.AX) Completes First IND Enabling Study For TPM(R) / Oxymorphone Patch 8/11/2014
Cellectar Biosciences  (NVLT) Files Investigational New Drug Application To Evaluate I-131-CLR1404 In Clinical Trials In Relapsed Or Refractory Multiple Myeloma 8/11/2014
IntelliCell BioSciences (SVFC) Files Pre-IND With FDA For Osteoarthritis Lead By Dr. James Andrews 8/4/2014
Fate Therapeutics (FATE) Announces FDA Clearance Of IND For Clinical Development Of PROHEMA In Inherited Metabolic Disorders 7/30/2014
Stemline Therapeutics, Inc. (STML) Announces Opening Of SL-401 Corporate IND And Start Of Clinical Trials In BPDCN And AML 7/28/2014
Lorus Therapeutics Inc. (LRP) Receives FDA Clearance Of IND To Initiate LOR-253 Clinical Program In Patients With AML, MDS And Other Blood Cancers 7/28/2014
MacroGenics, Inc. (MGNX)'s DART Candidate IND For Colorectal Cancer, MGD007, Cleared To Start Enrolling Patients 7/25/2014
Kinex Pharmaceuticals Announces Allowance Of The Investigational New Drug (IND) Application For KX2-391 Ointment By The United States FDA 7/24/2014
MiMedx Files Its Initial Investigational New Drug Application 7/23/2014
Lightlake Therapeutics Inc. (LLTP) Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 7/23/2014
Galmed Pharmaceuticals Announces FDA Clearance Of IND Of Armachol For The Treatment Of Fatty Liver Disorders 7/22/2014
AVANIR Pharmaceuticals (AVNR) Announces FDA Acceptance Of IND For AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 7/21/2014
InterMune, Inc. (ITMN) Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone 7/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Files Investigational New Drug Application And Device Master File With FDA For Novel Cell Replacement Therapy Product Candidate Designed To Treat Patients With Type 1 Diabetes 7/17/2014
AtheroNova Inc. (AHRO.OB) Announces Pre-IND Filing Under Section 505(b)(2) 7/15/2014
Rock Creek Pharmaceuticals Issues Update On U.S. Investigational New Drug Application 7/14/2014
FDA To Expedite Review Of Purdue Pharma L.P. Once-Daily Painkiller Tablet 7/8/2014
University of Pennsylvania's Personalized Cellular Therapy For Leukemia Receives FDA's Breakthrough Therapy Designation 7/7/2014
Curis, Inc. (CRIS) Announces Investigational New Drug Application Filing By Roche (RHHBY) To Initiate A Phase 2 Study Of Erivedge® (Vismodegib) In Idiopathic Pulmonary Fibrosis 6/23/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Chinese FDA Accepts Phase 2 IND For RGN-259 For Dry Eye 6/23/2014
MiMedx Expects To File Its First Investigational New Drug Application In July 6/19/2014
GW Pharmaceuticals Announces Physician Reports Of Epidiolex®: Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy From Physician-Led Expanded Access Treatment Program 6/17/2014
Regen BioPharma , A Majority Owned Subsidiary Of Bio-Management, Provides Update On Hemaxellerate I™ IND For Treatment Of Drug Resistant Aplastic Anemia 5/13/2014
GW Pharmaceuticals Receives Investigational New Drug (IND) From FDA For Phase 2/3 Clinical Trial Of Epidiolex® In The Treatment Of Dravet Syndrome 5/7/2014
Kinex Pharmaceuticals Receives FDA Allowance For Oratecan, An Oral Form Of Irinotecan With Enhanced Gastrointestinal Absorption, The Second U.S. IND Based On The Orascovery Technology Platform 5/5/2014
Ruthigen Submits Investigational New Drug (IND) Application For Clinical Trial Of RUT58-60 5/2/2014
NeuroNascent, Inc. Successfully Completes Pre-IND Meeting With FDA For Alzheimer's Disease Therapeutic 4/22/2014
Stemline Therapeutics, Inc. (STML) Announces FDA Acceptance Of IND For SL-701, A Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors 4/8/2014
FDA Lifts Clinical Hold On Oxygen Biotherapeutics, Inc. (OXBT)'s Program 3/31/2014
Geron Corporation (GERN) Says FDA Halts Patient Enrollment In Another Cancer Trial 3/21/2014
Summit Corporation Announces FDA Clearance Of IND Application For Phase 2 Study Of SMT19969 To Treat C. Difficile Infection 3/18/2014
IntelliCell BioSciences (SVFC) Announces It Will File An IND For Osteoarthritis Of The Knee In Conjunction With The Andrews's Research And Educational Foundation 3/17/2014
PharmaRoth Labs, Inc. Announces Results From FDA Application 3/17/2014
Geron Corporation (GERN) Tanks As FDA Halts Development Of Blood Disorder Drug 3/13/2014
Celsus Therapeutics (CLTX) Provides Update On MRX-6 From FDA Pre-IND Meeting 3/12/2014
Alcobra (ADHD) Announces FDA Clearance Of IND For Metadoxine Extended Release (MDX) 3/6/2014
Omeros Corporation (OMER) Submits IND To Advance OMS721 Phase 2 Clinical Program 3/4/2014
TONIX Pharmaceuticals, Inc. Completes Pre-IND Meeting With FDA On TNX-201 For Episodic Tension-Type Headache: Clinical Development To Begin In 4Q 2014 3/3/2014
Ignyta Announces Submission Of IND For RXDX-101 2/27/2014
rEVO Biologics Announces The Submission Of An IND For Atryn® In Preeclampsia 2/25/2014
International Stem Cell Corporation Completes Pre-IND Meeting With FDA For Parkinson's Disease Cell Therapy 2/18/2014
Regado Biosciences, Inc. (RGDO), Announces FDA Acceptance Of IND For REG2 2/13/2014
BioMarin Pharmaceutical Inc. (BMRN) Announces Selection Of NAGLU Fusion Protein Drug Development Candidate BMN 250 For The Treatment Of Sanfilippo B (MPS IIIB) 2/11/2014
Galectin Therapeutics Supports Investigational New Drug (IND) Application For Its Galectin Inhibitor GR-MD-02 In Metastatic Melanoma 1/15/2014
Benitec, Inc. (BLT.AX) Release: Hepatitis C Trial To Proceed 1/14/2014
Wilson Therapeutics Announces Successful Filing Of U.S. IND To Advance WTX101 Development Program For Wilson Disease 1/14/2014
Kala Pharmaceuticals Announces IND Submission Of Its MPP-Formulated Loteprednol Etonbonate (LE-MPP) For Post-Cataract Surgery 1/6/2014
Harvard Apparatus Regenerative Technology Files Pre-IND Meeting Documents And Orphan Biologics Application With U.S. FDA 1/6/2014
Cellceutix (CTIX) Submits Application To Institutional Review Board to Commence Clinical Trials Of Anti-Psoriasis Drug Prurisol 1/6/2014
FDA Lifts Hold On Studies Testing Cell Therapeutics, Inc. (CTIC)'s Cancer Drug Tosedostat 1/2/2014
Shield Therapeutics Release: FDA Grants Approval Of IND To Commence A Phase 3 Pivotal Study For ST10 For The Treatment Of Iron Deficiency Anemia In Chronic Kidney Disease 12/16/2013
Interim Results From Gentium S.p.A.'s Treatment IND For Defibrotide And Additional Data On Defibrotide In The Prevention Of Acute Graft Versus Host Disease (Agvhd) Presented At The American Society of Hematology Annual Meeting 12/11/2013
Raptor Pharmaceutical Inc. (RPTP) Submits IND For RP103 For Leigh Syndrome And Other Mitochondrial Disorders 12/10/2013
Coronado Biosciences (CNDO) Announces IND Submission For TSO For The Treatment Of Moderate To Severe Chronic Plaque Psoriasis 12/9/2013
ARCA biopharma Announces FDA Acceptance Of Gencaro IND Application For The Treatment Of Atrial Fibrillation 12/4/2013
Chikujee Initiates IND-Enabling Study For Programmable Therapeutic-CT-187MDR For The Treatment Of Multidrug Resistant Ovarian Cancer 11/15/2013
Discovery Laboratories (DSCO) Receives FDA Clearance Of IND To Initiate AEROSURF® Phase 2 Clinical Program 11/13/2013
Innate Pharma (IPH.PA ): Launch of IND-Enabling Studies for IPH4102 11/8/2013
Star Scientific , Inc. Announces Leadership Transition, Acceleration of Plans for Submission of an IND to FDA for Pharmaceutical Version of Anatabine Compound 11/8/2013
Aclaris Therapeutics Initiates IND-Directed Program for A-101 for the Treatment of Seborrheic Keratosis, Common Type of Skin Tumor 11/6/2013
Repros Therapeutics Inc. (RPRX) Receives FDA Guidance for Proellex® Low Dose Oral Uterine Fibroid Clinical Program 11/5/2013
ARCA biopharma Announces IND Submission to FDA for Gencaro for the Treatment of Atrial Fibrillation 10/29/2013
Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer 10/22/2013
RedHill Biopharma Ltd. (RDHL) Announces FDA Acceptance of IND Application for RHB-105 (H. pylori) Phase 3 Study - to Commence Shortly 10/22/2013
Discovery Laboratories (DSCO) Announces IND Submission for AEROSURF® 10/18/2013
Flatley Discovery Lab, LLC Nominates Clinical Candidate for Treatment of Cystic Fibrosis 10/11/2013
CFDA Accepts Sihuan Pharmaceutical Holdings Group Ltd. 's Application for Clinical Trial Approval for Self-Developed Innovative Oncology Drug Pirotinib 10/10/2013
StemCells Inc. (STEM) Receives FDA Authorization of IND for Spinal Cord Injury 10/2/2013
Advanced Cell Technology Files Investigational New Animal Drug (INAD) Application With FDA to Treat 10 Different Disease Indications Using Pluripotent Stem Cells 9/19/2013
GenKyoTex S.A. Receives FDA IND Approval for Phase II Clinical Study With First in Class NOX Inhibitor GKT137831 9/9/2013
International Stem Cell Corporation Advances Parkinson's Disease Program Towards IND Stage 9/9/2013
Oramed Pharmaceuticals Inc. (ORMP.OB) Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes 9/3/2013
Transdermal Delivery Solutions Subsidiary, Hormone Replacement Technologies, Receives FDA Approval to Begin Pivotal Clinical Trials of Testagen® TDS for the Treatment of Low Testosterone 8/22/2013
To-BBB technologies BV Receives IND Approval for Novel Brain Cancer Drug, 2B3-101 8/19/2013
Altor BioScience Corporation Launches Its Proprietary IL-15 Superagonist ALT-803 Into Clinical Trials Against Cancer 8/15/2013
GW Pharmaceuticals Opens an Investigational New Drug Application (IND) in the United States for a Sativex® Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis 8/14/2013
Atlantic Pharmaceuticals, Inc. Announces Successful Pre-IND Meeting With the FDA on Immediate Release, Abuse-Deterrent Hydrocodone 8/13/2013
Jubilant BioSys Ltd. Announces Successful Filing of Investigational New Drug With US-based Endo Pharmaceuticals (ENDP) 8/7/2013
ImmunoGen, Inc. (IMGN) Announces FDA Acceptance of IND for Company's Novel EGFR-Targeting ADC, IMGN289 8/2/2013
Oramed Pharmaceuticals Inc. (ORMP.OB) Submits Pre-IND Meeting Request to FDA for Its Oral Exenatide Capsule ORMD-0901 7/30/2013
PreScience Labs Announced that the FDA Accepts IND Application for Novel Oncology Drug 7/24/2013
Charleston Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting on New Migraine Treatment CL-H1T 7/23/2013
Kinex Pharmaceuticals Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel That is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US 7/22/2013
Genmab A/S (GEN.CO) Files IND for HuMax-TF-ADC 7/18/2013
Rexahn Pharmaceuticals, Inc. Announce IND Submission for RX-3117 7/15/2013
Pluristem Therapeutics (PSTI)'s South Korean Partner Files IND With Korean FDA for PLX Cells 7/8/2013
Astex Pharmaceuticals (ASTX) Announces IND Candidate: ASTX727 a Potential Best-in-Class Oral Hypomethylator 7/8/2013
Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 7/8/2013
La Jolla Pharmaceutical Company (LJPC) Announces FDA Acceptance of IND for LJPC-501 7/2/2013
FDA Granted Fast Track Designation for Genervon's Breakthrough Biotechnology Multi-Target ALS Drug GM604 Expediting Drug Approval Process 6/27/2013
TherapeuticsMD, Inc. Investigational New Drug Filing Accepted by FDA 6/13/2013
FDA Accepts IND Application for Edge Therapeutics' EG-1962 (nimodipine microparticles) 6/10/2013
Bio-Matrix Scientific Group Inc. (BMSN.OB)'s Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program 6/7/2013
AVANIR Pharmaceuticals (AVNR) Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting With FDA 6/5/2013
La Jolla Pharmaceutical Company (LJPC) Submits IND for LJPC-501 6/4/2013
Sunshine Biopharma, Inc. Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells 6/4/2013
Biovista and the CFIDS Association of America Achieve Drug Repositioning Milestone With Pre-IND Meeting 5/29/2013
Omeros Corporation (OMER) Release: Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 5/23/2013
Perosphere Inc. Receives FDA IND Clearance to Initiate Clinical Investigations of the Safety and Efficacy of PER977 to Reverse the Activity of Anticoagulation Therapies Including Factor Xa- and IIa-Inhibitors 5/22/2013
Oramed Pharmaceuticals Inc. (ORMP.OB) Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 5/17/2013
Enanta Pharmaceuticals, Inc. Release: Breakthrough Therapy Designation From the FDA Granted to Investigational HCV Regimen Containing Protease Inhibitor ABT-450 5/6/2013
RNL Bio Files IND to Commence Phase II Clinical Trial of RNL-JointStem for Osteoarthritis in the United States 5/2/2013
R-Tech Ueno Receives FDA IND Approval for RU-101 (r-HSA) to Treat Severe Dry Eye 4/26/2013
SK Bio-Pharmaceuticals Announces FDA's Authorization of IND for SKL15508 4/17/2013
FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment 4/16/2013
Oramed Pharmaceuticals Inc. (ORMP.OB) Submits New IND Application for Oral Insulin Trial in the US 4/11/2013
Boston Therapeutics, Inc. Requests an IND Meeting With the FDA for PAZ320 to Reduce Postprandial Hyperglycemia in Type 2 Diabetes 4/11/2013
Lipid Therapeutics Successfully Files a U.S. IND for LT-02, a Novel Barrier Function Therapy for Ulcerative Colitis 4/10/2013
ERYtech Pharma Receives FDA IND Clearance to Initiate a Clinical Study in Acute Lymphoblastic Leukemia in the U.S. 4/3/2013
Cleveland Biolabs Inc. (CBLI) and Incuron Announce Notice of Allowance From FDA to Commence Clinical Testing With CBL0137 4/2/2013
Soligenix (SNGX.OB) Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis 3/27/2013
Regen BioPharma Receives IND From FDA for HemaXellerate 3/18/2013
Immunotech Laboratories in Discussions for Pre-"IND" Testing of Aids-HIV "IPF" Treatment in the USA 3/18/2013
Sunshine Biopharma, Inc. Commences Negotiations With Contract Manufacturing Organizations for Production of Its Multidrug-Resistant Breast Cancer Drug, Adva-27a 3/14/2013
La Jolla Pharmaceutical Company (LJPC) Announces FDA Agreement With Proposed IND Submission for LJPC-501 in Hepatorenal Syndrome 3/4/2013
Sunshine Biopharma, Inc. Reports on IND Research for Its Novel Breast Cancer Drug Candidate, Adva-27a 2/26/2013
Ampio Pharmaceuticals, Inc. (AMPE) Modifies Ampion™ IND for Osteoarthritis of the Knee to Include a Dose Escalation Run-In Study and Prepares to Launch Pivotal Clinical Trial 2/25/2013
Scioderm's Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA 2/14/2013
FDA Agreement on Mesoblast Limited's Use of Singapore Manufacturing Facility for Clinical Trial Production of Proprietary Mesenchymal Precursor Cells 2/13/2013
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I™ Stem Cell Drug for Aplastic Anemia 2/5/2013
Galectin Therapeutics Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver Disease 1/31/2013
ImmunoCellular Therapeutics, Ltd' Investigational New Drug (IND) Application for ICT-140 Allowed by the FDA 1/29/2013
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate™ Bone Marrow Failure Product 1/25/2013
PledPharma Release: FDA Has Approved IND Application for Clinical Trial With PledOx in the U.S. 1/22/2013
Ampio Pharmaceuticals, Inc. (AMPE) Announces Active IND for Optina™ for the Treatment of Diabetic Macular Edema (DME) 1/22/2013
Clearside Biomedical Announces Plans for Clinical Testing of CLS1001 (Triamcinolone Acetonide) Suprachoroidal Injectable Suspension for the Treatment of Some Eye Diseases 1/10/2013
Soligenix (SNGX.OB) Receives IND Clearance From FDA to Initiate Program Evaluating OrbeShieldTM as a Therapy for Gastrointestinal Acute Radiation Syndrome 1/4/2013
TG Therapeutics, Inc. (MHA) Announces FDA Clearance to Commence Clinical Trials of Its Novel, PI3K-Delta Specific Inhibitor, TGR-1202, Under Its Recently Filed U.S. Investigational New Drug (IND) Application 1/3/2013
FDA Clears IND for First Clinical Trial Protocol Developed Using Crowdsourcing 12/18/2012
Amarin Corporation PLC (AMRN) Announces Completion of Dosing in a Fixed-Dose Combination Study With Vascepa® and a Leading Statin 12/17/2012
Invion Announces Successful Pre-Ind Meeting on INV103 (Cpn10) for the Treatment of Lupus 12/13/2012
Results From Gentium S.p.A.'s Treatment IND for Defibrotide Presented at the American Society of Hematology Annual Meeting 12/13/2012
Sunshine Biopharma, Inc. Completes Another IND-Enabling Study: Adva-27a is Found to be Effective Against Multidrug Resistant Uterine Cancer Cells 12/10/2012
La Jolla Pharmaceutical Company (LJPC) Announces FDA Approval of IND 12/5/2012
Sunshine Biopharma, Inc. Completes Six IND-Enabling Studies for Its Anticancer Compound, Adva-27a 12/4/2012
Galapagos NV (GLPG.BR) Opens IND for GLPG0634 in the U.S. 12/3/2012
Avaxia Biologics, Inc. Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis 11/27/2012
AtheroNova Inc. (AHRO.OB) Announces Milestone Filing of IND in Russian Federation 11/13/2012
Hanmi Pharmaceutical, Co., Ltd and Kinex Pharmaceuticals Announced Korean FDA Allowance of the KX01 IND Application 11/7/2012
TSRL, Inc. Reaches a Key Milestone With Pre-IND Meeting 10/26/2012
TONIX Pharmaceuticals, Inc. Completes Pre-IND Meeting With FDA for Potential New Treatment for Post-Traumatic Stress Disorder 10/24/2012
Avedro, Inc. Release: Keraflex® Keratoconus Treatment Study Begins in U.S. 10/12/2012
Genesis Biopharma, Inc. Receives FDA Meeting Minutes From Contego™ Pre-IND Meeting 10/11/2012
Sunshine Biopharma, Inc. Receives Scale-Up Manufacturing Protocol for Its Lead Anti-Cancer Compound, Adva-27a 10/9/2012
Tesaro, Inc. Announces Clearance of Investigational New Drug Application for TSR-011 10/3/2012
Investigational New Drug Application Cleared for Omeros Corporation (OMER)' Lead Compound in PDE10 Program 10/2/2012
Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases 9/12/2012
Cold Genesys, Inc. Continuing Development of CG0070 Oncolytic Virus With GMCSF Expression 9/7/2012
Omeros Corporation (OMER) Files Investigational New Drug Application for Lead Compound in PDE10 Program 9/6/2012
Soligenix (SNGX.OB) Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate SGX203 as Therapy for Pediatric Crohn's Disease 9/6/2012
Invion Limited Release: Pre-Ind Meeting for Xtoll in Lupus Scheduled With FDA 9/5/2012
Proacta Inc. Announces IND Allowance for PR610 8/29/2012
Apexigen Announces the Filing of an IND by its Partner, 3SBio Inc. (SSRX) 8/16/2012
Isconova's Adjuvant Matrix-M Approved by FDA for an IND Clinical Trial 8/15/2012
Ferrer Submits IND for Arasertaconazole Nitrate, a Safe, Fast-Acting Topical Antifungal in Development for Vulvovaginal Candidiasis 8/7/2012
Ampio Pharmaceuticals, Inc. (AMPE) Announces Successful Pre-IND Meeting With the Ophthalmology Division of the FDA on Optina™ for the Treatment of Diabetic Macular Edema 8/1/2012
Camargo Pharmaceutical Services Fast Tracks 505(b)(2) Indian Products 7/24/2012
pSivida Corp (PSDV) Receives FDA Clearance for Pivotal Trials for Injectable Sustained-Release Micro-Insert to Treat Uveitis 7/19/2012
TherapeuticsMD, Inc. Announces Plans in Hormone Therapy That Concur With the Recent Joint Statement from NAMS, ASRM and The Endocrine Society 7/10/2012
Capricor Announces FDA Approval to Initiate ALLSTAR Trial of Allogeneic Stem Cell Therapy in Patients Following Heart Attack 7/9/2012
Ampio Pharmaceuticals, Inc. (AMPE) Reports Successful Type B Pre-IND Meeting with the FDA for Its Drug Zertane™ to Treat Premature Ejaculation (PE) 6/21/2012
AVANIR Pharmaceuticals (AVNR) Announces FDA Acceptance Of IND For AVP-923 For The Treatment Of Agitation In Patients With Alzheimer's Disease 6/11/2012
Arrowhead Research Corporation (ARWR) Advances ARC-520 into IND-Enabling Studies for the Treatment of Hepatitis B and Provides Guidance on Development Timeline 6/6/2012
FivePrime Therapeutics, Inc. Announces That Human Genome Sciences Files U.S. IND for HGS1036/FP-1039 FGF Ligand Trap 6/4/2012
RXi Pharmaceuticals (RXII) Receives FDA Clearance to Begin Clinical Trial With RXI-109 5/31/2012
Soricimed Biopharma, Inc. Receives IND Clearance to Commence Phase I Trial of New Cancer Drug 5/30/2012
Zogenix, Inc. Submits IND for Second DosePro(R) Candidate Relday(TM) 5/30/2012
RetroSense Therapeutics Completes pre-IND Meeting for RST-001 5/24/2012
Cellceutix (CTIX) Files Amended IND With FDA for Its Novel p53 5/21/2012
Neuren Pharmaceuticals Limited Holds Pre-IND Meeting on Proposed Rett Syndrome Clinical Trials With FDA 5/17/2012
Ambit Biosciences and Teva Pharmaceutical Industries Limited (TEVA) Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 5/17/2012
TG Therapeutics, Inc. (MHA) Announces Investigational New Drug (IND) for TGTX-1101, Receives Clearance by the FDA to Commence Clinical Trials in the U.S. 5/15/2012
Ampio Pharmaceuticals, Inc. (AMPE) Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion™ for the Treatment of Chronic Pain of Osteoarthritis of the Knee and Schedules May 16th Webcast to Update Shareholders 5/11/2012
Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy 5/4/2012
Lixte Biotechnology Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound 5/1/2012
Cleveland Biolabs Inc. (CBLI) and Incuron Announce Russian Regulatory Allowance of IND for Phase 1B Trial of CBLC137 4/30/2012
Tengion Inc. Announces IND Filing for Neo-Kidney Augment Expected During First Half of 2013 4/18/2012
Medgenics, Inc. Files IND Application for EPODURE Biopump Phase IIb Anemia Study in Dialysis Patients 4/17/2012
ImmunoGen, Inc. (IMGN) Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853 4/17/2012
FDA Schedules a Date With Cellceutix (CTIX) on New Psoriasis Drug 4/16/2012
Cerecor Inc. Announces Clearance of IND for FP01 4/11/2012
Marshall Edwards, Inc. (MSHL) Receives FDA Approval of Investigational New Drug Application for Clinical Testing of Oncology Drug Candidate ME-344 4/10/2012
Ampio Pharmaceuticals, Inc. (AMPE) Submits Pre-IND Package on Zertane to FDA 4/9/2012
Frontage Laboratories Begins Early Phase Clinical Program for Hisun Pharma 4/4/2012
Cannabis Science Inc. Continues Forward with FDA IND Process as Patients Report Successful Cancer Treatments 4/2/2012
NanoViricides, Inc. (NNVC.PK) Announces Successful Pre-IND Meeting With the US FDA 4/2/2012
Ablynx Receives Milestone Payment as Collaborator Receives IND Approval for a Nanobody in Oncology 4/2/2012
Tengion Inc. Announces Significant Advances in Neo-Urinary Conduit(TM) and Neo-Kidney Augment(TM) Programs 3/27/2012
FDA Accepts PaxVax, Inc.’s IND for Single-Dose Oral Cholera Vaccine 3/19/2012
Cellceutix (CTIX) Files Pre-IND Documentation to FDA for New Psoriasis Drug 3/12/2012
Cannabis Science Inc. Confirms Target Indication for FDA and Prepares for Pre-IND Meeting with the FDA with its Team of FDA Specialists 3/12/2012
Viral Genetics Inc. (VRAL) Submits Pre-IND Document for Lyme Disease Drug Candidate to FDA 3/7/2012
NanoViricides, Inc. (NNVC.PK) Announces US FDA has Confirmed Pre-IND Meeting Date 3/5/2012
Tau Therapeutics, LLC IND Accepted by FDA for Novel Cancer Drug 2/28/2012
S1 Pharmaceuticals, Inc. Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) 2/21/2012
Coronado Biosciences Announces IND Submission for CNDO-109 for the Treatment of Relapsed Acute Myeloid Leukemia 2/14/2012
Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation 2/7/2012



//-->